(Q83387767)

English

Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer

scientific article published on 08 February 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

based on heuristic

inferred from title

author name string

Yan-Xia Shi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Yu-Ting Tan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Zhong-Yu Yuan

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Shu-Sen Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Rou-Jun Peng

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Xin An

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Ye Cao

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Ying Jin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Xiu-Yu Cai

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Yue-Li Sun

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Xiao-Yu Teng

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Dong-Geng Liu

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

8 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

39-47

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21302001%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuing trastuzumab beyond progression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stress pathways and heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First--select the target: better choice of adjuvant treatments for breast cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The distinctive nature of HER2-positive breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21302001

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83387767&oldid=2221396476"